These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2159679)

  • 1. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers.
    Gonczol E; Ianacone J; Ho WZ; Starr S; Meignier B; Plotkin S
    Vaccine; 1990 Apr; 8(2):130-6. PubMed ID: 2159679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.
    Yue Y; Zhou SS; Barry PA
    J Gen Virol; 2003 Dec; 84(Pt 12):3371-3379. PubMed ID: 14645918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
    Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
    Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
    Hu X; Karthigeyan KP; Herbek S; Valencia SM; Jenks JA; Webster H; Miller IG; Connors M; Pollara J; Andy C; Gerber LM; Walter EB; Edwards KM; Bernstein DI; Hou J; Koch M; Panther L; Carfi A; Wu K; Permar SR
    J Infect Dis; 2024 Aug; 230(2):455-466. PubMed ID: 38324766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.
    Thomas M; Kropff B; Schneider A; Winkler TH; Görzer I; Sticht H; Britt WJ; Mach M; Reuter N
    J Virol; 2021 Aug; 95(18):e0065721. PubMed ID: 34160252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease.
    Alberola J; Domínguez V; Cardeñoso L; López-Aldeguer J; Blanes M; Estellés F; Ricart C; Pastor A; Igual R; Navarro D
    J Med Virol; 1998 Aug; 55(4):272-80. PubMed ID: 9661835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
    Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
    EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.
    Marshall GS; Rabalais GP; Stout GG; Waldeyer SL
    J Infect Dis; 1992 Feb; 165(2):381-4. PubMed ID: 1309850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
    Schrader JW; McLean GR
    Immunol Lett; 2007 Sep; 112(1):58-60. PubMed ID: 17714794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
    Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate.
    Gönczöl E; Berensci K; Pincus S; Endresz V; Méric C; Paoletti E; Plotkin SA
    Vaccine; 1995 Aug; 13(12):1080-5. PubMed ID: 7491815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.
    Gerna G; Percivalle E; Perez L; Lanzavecchia A; Lilleri D
    J Virol; 2016 Jul; 90(14):6216-6223. PubMed ID: 27122579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
    Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.
    Navarro D; Lennette E; Tugizov S; Pereira L
    J Med Virol; 1997 Aug; 52(4):451-9. PubMed ID: 9260696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization.
    Endresz V; Kari L; Berencsi K; Kari C; Gyulai Z; Jeney C; Pincus S; Rodeck U; Méric C; Plotkin SA; Gönczöl E
    Vaccine; 1999 Jan; 17(1):50-8. PubMed ID: 10078607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
    Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
    PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Little role of anti-gB antibodies in neutralizing activity of patient's sera with human cytomegalovirus (HCMV) infection.
    Park JW; Kim DJ; Kim J; Park CG; Hwang ES; Cha CY
    J Korean Med Sci; 2000 Apr; 15(2):133-8. PubMed ID: 10803687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant.
    Muñoz I; Gutiérrez A; Gimeno C; Farga A; Alberola J; Solano C; Prósper F; García-Conde J; Navarro D
    J Med Virol; 2001 Sep; 65(1):77-84. PubMed ID: 11505447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.